AstraZeneca PLC Release: BRILINTA (Ticagrelor) Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of STEMI Patients

Published: Dec 18, 2012

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) announced today that a combined panel of experts from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) have updated their guidelines to include a Class I recommendation for use of the oral antiplatelet (OAP) medicine BRILINTA® (ticagrelor) tablets in patients with ST-elevation myocardial infarction (STEMI) managed invasively.1 With this latest guidelines update, BRILINTA is included in more than 10 major acute coronary syndrome (ACS) treatment guidelines globally.1-11 “The U.S. Cardiology community is again acknowledging the clinical value of BRILINTA,” said James Ferguson, MD, Executive Director, Medical Affairs and Strategic Development, US, and Vice President for Global Medical Affairs. “This significant milestone, along with the inclusion in the NSTEMI Guidelines in July, solidifies the position of BRILINTA in multiple ACS guidelines as an important part of standard of care for both STEMI and NSTEMI patients.”2

Back to news